The first ever mRNA vaccine for malaria is being tested in a multi-center clinical trial coordinated by the University of Maryland School of Medicine’s Center for Vaccine Development. The multi-antigen vaccine candidate developed by BioNTech could help protect people from malaria in areas where the disease is endemic.
The University of Maryland School of Medicine serves as the anchor for a large academic health center which aims to provide the best medical education, conduct the most innovative biomedical research and provide the best patient care and community service to Maryland and beyond.
23 окт 2024
